This page contains exclusive content for the member of the following sections: TTS, ITA
Presenter: Cal, Matsumoto, Washington, United States
Authors: Cal Matsumoto1, Stuart Kaufman1, Raffaele Girlanda1, Eddie Island1, Cheryl Little1, Kirti Shetty1, Erin Fennelly1, Thomas Fishbein1
Cal Matsumoto, Stuart Kaufman, Raffaele Girlanda, Eddie Island, Cheryl Little, Kirti Shetty, Erin Fennelly, Thomas Fishbein
Transplant Institute, Georgetown University Hospital, Washington, DC, United States
Human CMV infection, a member of the herpes virus family, has routinely been established as a risk factor for increased morbidity and mortality in intestinal transplantation (iTx). Reactivation of latent CMV has been postulated to be a result of an increased proinflammatory state of cytokines and chemokines. In inflammatory bowel disease, a relationship has been established between colitis exacerbations and the reactivation of latent CMV. We have previously demonstrated the association between NOD2 polymorphisms and the abnormal epithelial immune function in iTx recipients. The purpose of this study is to evaluate the relationship between NOD2 mutant iTx recipients and the incidence of CMV infection.
35/134 (25.9%) iTx recipients were identified as having at least one NOD2 polymorphism. 8/35 NOD2 Mutants were CMV serotype matching neg/neg and were excluded from CMV reactivation analysis. Likewise, 50/99 NOD2 Wildtype were neg/neg. 18/35 NOD2 Mutants and 38/99 NOD2 Wildtype had a liver-inclusive intestinal graft. Overall Freedom from CMV was not different between the 2 groups with NOD2 Mutant (69.6%) vs. NOD2 Wildtype (75.3%) p=ns. Recurrent CMV, however, was more prevalent in the NOD2 Mutant group 7/35 vs 4/99 (p=0.019). In evaluation of CMV reactivation (excluding CMV neg/neg matching), no significant difference was noted in overall Freedom from CMV between the 2 groups however, NOD2 mutants in this group had a significantly higher incidence of CMV recurrence than the NOD2 Wildtype, 7/27 vs. 4/47 respectively, (p = 0.04).
NOD2 Mutation in iTx recipients appears to play a role in the incidence of CMV recurrence after initial CMV infection. Perhaps an chronically altered and dysregulated inflammatory state in the NOD2 Mutant iTx recipient plays an important role in the increased recurrence of CMV infection in this population. A role for a more aggressive CMV prophylaxis in this subset of iTx recipients appears warranted.
By viewing the material on this site you understand and accept that:
The Transplantation Society
505 Boulevard René-Lévesque Ouest
Montréal, QC, H2Z 1Y7